With few specifics, Recursion underwhelms with first Phase 2 readout, but ‘plans to advance’ drug
Recursion reported mixed data Tuesday from its first Phase 2 study, in a disappointing start to an expected frenzy of clinical results.
The Salt Lake …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
